TOKYO, April 23, 2018 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., ” Astellas ” ) today announced that it submitted on March 23, 2018, a new drug application (NDA) for marketing approval of gilteritinib… (Source: Drugs.com – New Drug Applications)



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image